A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)
Article in ESMO Open (February 2024)
The most recent citing publications are shown below. View all 8 publications that cite this research output on Dimensions.
Adverse events of neoadjuvant combination immunotherapy for resectable cancer patients: a systematic review and meta-analysis
Article in Frontiers in Immunology (January 2024)
Postmarketing surveillance of nivolumab plus ipilimumab combination therapy in Japanese patients with unresectable malignant melanoma
Article in The Journal of Dermatology (June 2023)